ReviewJournal of immunology research2014
Current vaccine trials in glioblastoma: a review.
Review in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 85 citations in OpenAlex.
- Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.Frontiers in immunology · 2018Trial
- Glioblastoma stem cell metabolism and immunity.Cancer metastasis reviews · 2024Review
- Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.International journal of molecular sciences · 2023Review
- Review
- Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier.Frontiers in immunology · 2023Review
- Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies.Cancer biology & medicine · 2022Article
- The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic AdenocarcinomaJournal of oncology · 2022Article
- Review
- Review
- The Regulation of ROS- and BECN1-Mediated Autophagy by Human Telomerase Reverse Transcriptase in Glioblastoma.Oxidative medicine and cellular longevity · 2021Article
- T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges.Frontiers in oncology · 2021Review
- A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.Journal of neuro-oncology · 2021Review
- Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma.Frontiers in oncology · 2020Review
- Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma.Journal of clinical medicine · 2019Article
- Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma.Frontiers in oncology · 2018Article
- Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.Neuroimmunology and neuroinflammation · 2018Article
- Engineering challenges for brain tumor immunotherapy.Advanced drug delivery reviews · 2017Review
- Tumor Vaccines for Malignant Gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- The Safety of available immunotherapy for the treatment of glioblastoma.Expert opinion on drug safety · 2017Review
- MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.Journal of immunology research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most common primary brain tumor, and despite aggressive therapy with surgery, radiation, and chemotherapy, average survival remains at about 1.5 years. The highly infiltrative and invasive nature of GBM requires that alternative treatments for this disease be widespread and targeted to tumor cells. Immunotherapy in the form of tumor vaccines has the potential to meet this need. Vaccines against GBM hold the promise of triggering specific and systemic antitumor immune responses that may be the key to eradicating this unrelenting cancer. In this review, we will discuss past and present clinical trials of various GBM vaccines and their potential impact on the future care of GBM patients. There have been many promising phase I and phase II GBM vaccine studies that have led to ongoing and upcoming phase III trials. If the results of these randomized trials show a survival benefit, immunotherapy will become a standard part of the treatment of this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.